leflunomide has been researched along with MS (Multiple Sclerosis) in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012." | 8.89 | Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. ( O'Doherty, C; Polasek, TM; Rowland, A; Sorich, MJ; Wiese, MD, 2013) |
| "Teriflunomide has shown a favorable safety and efficacy profile in RRMS and is a therapeutic option for a distinct group of adult patients with RRMS." | 6.55 | From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. ( Aly, L; Hemmer, B; Korn, T, 2017) |
| "Birth defects were reported in 44 babies/fetuses/embryos from 587 pregnancies, with 2 reporting at least 3 minor defects and 20 reporting major defects." | 5.56 | Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. ( Afsar, S; Davenport, L; Henson, LJ; Poole, EM; Purvis, A; Truffinet, P, 2020) |
| "Teriflunomide, the active metabolite of leflunomide, is a disease-modifying therapy drug used for the treatment of multiple sclerosis (MS), yet the complications associated with this drug remain not fully understood." | 5.41 | Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report. ( Feng, J; Qin, X; Xu, K; Yang, S; Yu, G; Zhang, M; Zheng, P, 2023) |
| "Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012." | 4.89 | Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. ( O'Doherty, C; Polasek, TM; Rowland, A; Sorich, MJ; Wiese, MD, 2013) |
| " Here, we investigated the efficacy of leflunomide and its mode of action in experimental autoimmune encephalomyelitis (EAE), which is a T helper cell type 1 cell-borne disease model to simulate inflammatory aspects of multiple sclerosis and was induced in Lewis rats by adoptive transfer of myelin basic protein (MBP)-specific T line cells." | 3.72 | Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. ( Jung, S; Korn, T; Magnus, T; Toyka, K, 2004) |
| "Teriflunomide has shown a favorable safety and efficacy profile in RRMS and is a therapeutic option for a distinct group of adult patients with RRMS." | 2.55 | From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. ( Aly, L; Hemmer, B; Korn, T, 2017) |
| "Birth defects were reported in 44 babies/fetuses/embryos from 587 pregnancies, with 2 reporting at least 3 minor defects and 20 reporting major defects." | 1.56 | Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. ( Afsar, S; Davenport, L; Henson, LJ; Poole, EM; Purvis, A; Truffinet, P, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, K | 1 |
| Zhang, M | 1 |
| Yang, S | 1 |
| Yu, G | 1 |
| Zheng, P | 1 |
| Qin, X | 1 |
| Feng, J | 1 |
| Henson, LJ | 1 |
| Afsar, S | 1 |
| Davenport, L | 1 |
| Purvis, A | 1 |
| Poole, EM | 1 |
| Truffinet, P | 1 |
| Wiese, MD | 1 |
| Rowland, A | 1 |
| Polasek, TM | 1 |
| Sorich, MJ | 1 |
| O'Doherty, C | 1 |
| Bencsik, K | 1 |
| Rózsa, C | 1 |
| Vécsei, L | 1 |
| Aly, L | 1 |
| Hemmer, B | 1 |
| Korn, T | 2 |
| Magnus, T | 1 |
| Toyka, K | 1 |
| Jung, S | 1 |
| Burton, JM | 1 |
| O'Connor, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS[NCT03464448] | 30 participants (Actual) | Observational | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for leflunomide and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
Topics: Adult; Female; Humans; Hydroxychloroquine; Leflunomide; Lupus Erythematosus, Cutaneous; Multiple Scl | 2023 |
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Top | 2013 |
[TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Topics: Clinical Trials as Topic; Crotonates; Drug Administration Schedule; Humans; Hydroxybutyrates; Interf | 2015 |
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Topics: Administration, Oral; Animals; Crotonates; Drug Discovery; Humans; Hydroxybutyrates; Immunosuppressi | 2017 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Cl | 2007 |
3 other studies available for leflunomide and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide.
Topics: Adult; Congenital Abnormalities; Crotonates; Female; Humans; Hydroxybutyrates; Immunosuppressive Age | 2020 |
Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Topics: Animals; Crotonates; Drug Interactions; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; M | 2015 |
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Topics: Adoptive Transfer; Animals; Animals, Newborn; Antigens, CD; B7-2 Antigen; Cells, Cultured; Chemotaxi | 2004 |